drugset
drugset / Trial / NCT00205049

Pentoxifylline for Acute Alcoholic Hepatitis (AAH)

NCT00205049 ↗

Phase 1 Terminated 4 enrolled University of Wisconsin, Madison
NaSingle-groupDouble-blindTreatment

Summary

The goal of this study is to demonstrate the effectiveness of pentoxifylline compared to placebo in AAH while studying putative mechanisms that are plausible and testable. The main hypothesis is that pentoxifylline reduces the 90-day mortality of AAH.

Timeline

Start
2005-03
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentoxifylline Small molecule 400 mg Oral

Indications

alcoholic hepatitis